Document 0561
 DOCN  M9590561
 TI    Bispecific antibody-mediated cytotoxicity by CD4+ and CD8(+)-activated T
       cells generated from leukemia patients after allogeneic bone marrow
       transplantation.
 DT    9509
 AU    Hattori K; Tsukamoto H; Ohta S; Yabe M; Yabe H; Kato S; Takakura I; Ueda
       R; Habu S; Nishimura T; Department of Pediatrics, Tokai University
       School of Medicine,; Isehara, Japan.
 SO    Bone Marrow Transplant. 1995 Feb;15(2):193-8. Unique Identifier :
       AIDSLINE MED/95291217
 AB    The F(ab')2 bispecific antibody (BSAb) was prepared from anti-CD3 moAb
       and anti-CD10 moAb. The BSAb could react with both CD3+ T cells and
       CD10+ leukemia cells and triggered T cell-mediated cytotoxicity. To
       apply the BSAb to prevention of leukemic relapse after BMT, we
       investigated the generation of both CD4+ and CD8+ anti-tumor effector T
       cells from patient's PBMC 14 days after BMT. Neither CD4+ T cells nor
       CD8+ T cells, which were activated with immobilized anti-CD3 moAb plus
       IL-2, could lyse CD10+ leukemia cells by themselves, but they showed
       augmented cytotoxicity against CD10+ leukemia cells by targeting with
       anti-CD3 x anti-CD10 BSAb. Moreover, the activated CD4+ T cells were
       demonstrated to produce IL-2 and IFN-gamma when they were cultured with
       CD10+ leukemia cells in the presence of the BSAb. The BSAb-mediated
       cytotoxicity of activated T cells was demonstrated not only against the
       recipient leukemia cells but also against third party leukemia cells.
       These results suggested that anti-CD3 x anti-CD10 BSAb might be a good
       tool to prevent relapse after BMT in combination with activated CD4+ T
       cells and CD8+ T cells.
 DE    Antibodies, Monoclonal/*ADMINISTRATION & DOSAGE  Antigens,
       CD3/*IMMUNOLOGY  Bone Marrow Transplantation/*IMMUNOLOGY  Child  Child,
       Preschool  Cytotoxicity, Immunologic/DRUG EFFECTS  CD4-Positive
       T-Lymphocytes/*IMMUNOLOGY  CD8-Positive T-Lymphocytes/*IMMUNOLOGY
       Female  Graft Rejection/*PREVENTION & CONTROL  Human  Leukemia/SURGERY
       Lymphocyte Transformation/DRUG EFFECTS/IMMUNOLOGY  Male  Membrane
       Metallo-Endopeptidase/*IMMUNOLOGY  Support, Non-U.S. Gov't  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).